ASNDDK#6 by MGI
Ascendis Pharma A/S
Analysis last updated Jul 17, 2026. Market data (price, market cap) is the latest available and may differ.
Growth · Value − Threat = Opportunity. Each 0–100. How we score.
Overview
Ascendis Pharma is a Danish global biopharmaceutical company that develops long-acting prodrug therapies using its proprietary TransCon (Transient Conjugation) technology, which temporarily conjugates a linker to existing drug molecules to produce sustained-release versions requiring less frequent dosing. Revenue is generated from three marketed rare endocrinology products sold through specialty pharmacy channels: SKYTROFA (once-weekly growth hormone for pediatric growth hormone deficiency, approved 2021), YORVIPATH (once-weekly parathyroid hormone for hypoparathyroidism, approved 2024), and YUVIWEL (once-weekly C-type natriuretic peptide for achondroplasia, FDA-approved February 2026 and commercially launched April 2026). All three generate prescription revenues at 89% gross margins, and the company is transitioning to sustained free cash flow generation.
Create a free account to read the full thesis and every lens in detail.
The six lenses
The TransCon platform is protected by a dense and proprietary IP estate, and each commercialized product is further insulated by regulatory data exclusivity and Orphan Drug status, including seven years of U. S. exclusivity granted to YUVIWEL in March 2026. …
Learn the principle →At a market capitalization well below major biopharmaceutical peers, Ascendis carries virtually no size-based constraint on future compounding. YORVIPATH addresses a global hypoparathyroidism market where penetration is still in early innings; YUVIWEL targets an estimated 300,000 achondroplasia patients worldwide with a differentiated weekly regimen and EU approval anticipated in the fourth quarter of 2026; and SKYTROFA continues its international rollout. …
Learn the principle →The commercial ramp is demonstrating the operating leverage inherent in an 89% gross margin business: operating profitability emerged firmly in late 2025 and held through the first quarter of 2026, and management has guided to approximately 500 million euros in operating cash flow for full-year 2026 after operating near breakeven as recently as 2024. YORVIPATH delivered roughly 477 million euros in 2025 product revenue and continues scaling with over 1,000 new U. S. patient enrollments in a single quarter. …
Learn the principle →Net debt of approximately 324 million dollars is modest against a rapidly strengthening cash-flow profile, with the company generating positive free cash flow and guiding to meaningful operating cash generation in 2026 after years of development-stage losses. Gross margins at 89% provide a substantial cushion to fund ongoing R&D investment without reliance on dilutive equity raises. …
Learn the principle →Founder-CEO Jan Moller Mikkelsen has led Ascendis since its 2007 founding, guiding the TransCon platform through three consecutive FDA commercial approvals: SKYTROFA in 2021, YORVIPATH in 2024, and YUVIWEL in February 2026. Annual product revenue scaled from negligible levels to over 720 million euros by 2025 with the company reaching positive operating cash flow within a few years of its first commercial launch. …
Learn the principle →Rare endocrinology is a secular-growth industry that insulates Ascendis from economic cyclicality and most commodity pressures. Competitive encirclement is the primary live risk: BioMarin is actively adapting Voxzogo in achondroplasia with label expansions including hypochondroplasia, and BridgeBio Pharma has demonstrated positive data for an oral achondroplasia treatment that could shift the convenience calculus materially. In hypoparathyroidism, BridgeBio's encaleret and MBX's canvuparatide advance with mechanistically distinct approaches. YUVIWEL carries accelerated approval status requiring confirmatory trial data, creating a regulatory execution dependency. …
Learn the principle →Business profile
Health Care · Biotechnology
Management
How the people running it lead, execute, and allocate capital.
Under founder-CEO Jan Moller Mikkelsen, Ascendis achieved three consecutive FDA product approvals (SKYTROFA 2021, YORVIPATH 2024, YUVIWEL February 2026), scaling annual product revenue from negligible levels to over 720 million euros by 2025 while reaching positive operating cash flow. The company took the company public in 2015 and has executed each commercial launch sequentially while maintaining a deep R&D pipeline, demonstrating rare discipline in rare-disease drug development across a multi-product platform.
Scorecard
- Moat70Strong
- Runway83Strong
- Growth Engine79Strong
- Financials66Moderate
- Management77Strong
- Risks62Moderate
Six lenses, each 0–100 and rated Strong / Moderate / Weak; the swing factor most decides the outcome. What each lens means.
Fundamentals
How it makes money
Revenue by segment, sized by share. Click a segment for the full detail.
Valuation
Live market multiples, plus a separate estimate of what the business is worth. Information only, not a price target.
Forward Multiple. ~32x FY2026E FCF on ~$550M (management-guided €500M operating cash flow), expanding to ~$900M by 2027 as three products scale shared infrastructure; premium warranted by 89% gross margins, 40–47% revenue CAGR toward the €5B 2030 target, and unpriced TransCon oncology optionality
ConfidenceSolid60/100What's priced in: The market looks too cautious.
The reverse-DCF embeds 42% annual revenue growth at today's 7% FCF margin—but that flat-margin assumption is the critical flaw: the business is entering a steep margin expansion phase from 7% toward 30%+ as three rare-disease products compound over fixed shared infrastructure. At roughly 30x management-guided 2026 operating cash flow of €500M, the current price is giving the company only partial credit for that margin inflection and none for the TransCon oncology pipeline; fair value anchors modestly above the current market cap.
Competes with
Covered names link to their analysis; greyed names are private or outside our universe.
Scores over time
Each nightly run adds a point; trends build as history accumulates.
Think our analysis of Ascendis Pharma A/S missed the mark? We are always trying to improve Multibagger.